

DOCKET NO.: DMCI-0099

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Daphna Havkin-Frenkel, Andrzej Podstolski, Richard A. Dixon

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filin	g Date: Herewith	Examiner: Not yet assigned				
	VANILLIN BIOSYNTHETIC PA NIFOLIA	THWAY ENZYME FROM VANILLA				
		EXPRESS MAIL LABEL NO:EL719246398US DATE OF DEPOSIT: February 28, 2002				
		SNGLE942473				
Box	Patent Application					
	☐ Sequence ☐ Design					
	ant Commissioner for Patents ington, DC 20231					
Sir:	•					
	PATENT APPLICATION	ON TRANSMITTAL LETTER				
	Transmitted herewith for filing, plea	ase find				
$\boxtimes$	A Utility Patent Application under	37 C.F.R. 1.53(b).				
	It is a continuing application, as follows	lows:				
	☐ continuation ☐ divisional ☑	continuation-in-part of prior application number				
	A Design Patent Application (subm	itted in duplicate).				
	Request for Nonpublication is att	ached.				

loos//lw.orceor

DOCK	TET INC	J. : DIV	ICI-0099 - 2 - PATEN	1			
Includ	ing the	followii	ng:				
$\boxtimes$	New or Revised Specification, including pages 1 to 114 containing:						
	$\boxtimes$	Specif	ication				
	$\boxtimes$	Claims	s				
	$\boxtimes$	Abstra	ıct				
	☐ Substitute Specification, including Claims and Abstract.						
			The present application is a continuation application of Application No The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include nematter.				
			The present application is a continuation application of Application No	n			
	A copy of earlier application Serial NoFiled, including Specification, Claims and Abstract (pages 1 - @@), to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.						
			the following amendment to the Specification under the Cross-Reference optications section (or create such a section): "This Application:	е			

☐ is a continuation of ☐ is a divisional of ☐ claims benefit of U.S. provisional Application Serial No. \_\_\_\_\_\_\_filed \_\_\_\_\_\_\_

	DOC	EKET NO.: DMCI-0099 -3-	ATENT					
		Signed Statement attached deleting inventor(s) named in the prior application.						
		A Preliminary Amendment.						
	$\boxtimes$	Sheets of Formal Drawings.						
		Drawing view to publish:1						
		Petition to Accept Photographic Drawings.						
<u>.</u>		☐ Petition Fee						
10087714.022802	$\boxtimes$	An $\square$ Executed $\boxtimes$ Unexecuted Declaration or Oath and Power of Attorney.						
		An Associate Power of Attorney.						
		An  Executed Copy of Executed Assignment of the Invention to						
		□ A Recordation Form Cover Sheet.     □ Recordation Fee - \$40.00.  The prior application is assigned of record to  Priority is claimed under 35 U.S.C. § 119 of Patent Application No  filed in(country).      □ A Certified Copy of each of the above applications for which priority is claimed:     □ is enclosed.     □ has been filed in prior application Serial No filed	s 					
		Please enter the following amendment to the first sentence of the speci- (or create such a sentence): "This application claims benefit of internat application No, which was published under PCT Article in English."	ional					

DOCI	KET NO.: DMCI-0099 -4- PATENT
	Applicant(s) by its/their undersigned attorney, claims small entity status under 37 C.F.R. §1.27 as:
	an Independent Inventor
	☐ a Small Business Concern
	a Nonprofit Organization.
⊠	Diskette Containing DNA/Amino Acid Sequence Information.
$\boxtimes$	Statement to Support Submission of DNA/Amino Acid Sequence Information.
⊠	Sequence listing containing pages <u>1-19</u> .
	The computer readable form in this application, is identical with that filed in Application Serial Number, filed, In accordance with 37 CFR 1.821(e), please use the ☐ first-filed, ☐ last-filed or ☐ only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is ☐ included in the originally-filed specification of the instant application, ☐ included in a separately filed preliminary amendment for incorporation into the specification.
	Information Disclosure Statement.  Attached Form 1449.  Copies of each of the references listed on the attached Form PTO-1449 are

enclosed herewith.

A copy of Petition for Extension of Time as filed in the prior case.

Appended Material as follows:

200		J D LCI 007	_	Ü				
$\boxtimes$	Return Receipt Postcard (should be specifically itemized).							
	Other	Other as follows:						
FEE	CALCUI	LATION:						
	Cance	l in this applica	tion origin	al claims	of	the prior app	plication before	
		ating the filing ng purposes.)	fee. (At le	east one origin	nal independ	ent claim mu	st be retained	
888	*****	*******	****	SMALL	ENTITY	NOT SM	IALL ENTITY	
88				RATE	FEE	RATE	FEE	
DESI	GN APPLIC	ATION		\$165.00	s	\$330.00	\$	
UTIL	ITY APPLI	CATIONS BASE FI	EE	\$370.00	s	\$740.00	\$ 740.00	
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS								
		No. Filed	No. Extra					
	TOTAL CLAIMS	31 - 20 =	11	\$9 each	\$	\$18 each	\$ 198.00	
	NDEP. CLAIMS	5 - 3 =	2	\$42 each	\$	\$84 each	\$ 168.00	
	IRST PRES	SENTATION OF M T CLAIM	ULTIPLE	\$140	\$	\$280	\$ 0.00	
ADDITIONAL FILING FEE					\$		\$ 0.00	
TOTA	AL FILING	FEE DUE			\$		\$ 1106.00	
$\boxtimes$	A Check is enclosed in the amount of \$ 1106.00							
$\boxtimes$	The Commissioner is authorized to charge payment of the following fees and to							
		refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.						
		The foregoing	g amount d	ue.				
	$\boxtimes$	-	-		cluding fees	for the prese	entation of extr	
	claims under 37 C.F.R. 1.16.							

MI

- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: Feb 28 2002

Sott & Sieli

Scott E. Scioli Registration No. 47,930

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

@2001 WW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

l	n	R	e A	۱p	p	lic	at	tic	n	01	:
---	---	---	-----	----	---	-----	----	-----	---	----	---

Havkin-Frenkel, et al.

Serial No.: Not assigned yet
Filing Date: Herewith

Group Art Unit: Not assigned yet

Examiner: Not assigned yet

For: Vanillin Biosynthetic Pathway Enzyme From Vanilla Planifolia

Assistant Commissioner for Patents

Washington, D.C. 20231

EXPRESS MAIL LABEL NO: EL719246398US DATE OF DEPOSIT: February 28, 2002

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

<u></u> x	I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the
	contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR $\S1.821(c)$ and $(e)$ , respectively are the same.
$\boxtimes$	I hereby state that the submission filed in accordance with 37 CFR $\S1.821(g)$ does not include new matter.
	I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed
	I hereby state that the amendments, made in accordance with 37 CFR §1.825(a) included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
	I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CER \$1.825(b) is the same as the amonded Sevence Listing.

IDDB7714.DEGSDE

☐ I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR \$1.825(d), contains identical data to that originally filed.

Date: Feb 28, 2002

Scott E Scioli Registration No. 47,930

th E. Sioli

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2001 WW